News

Morning briefing: Literacy Capital sells Kernel loans for £6.5m; RTW-backed Windward Bio soars 68% on Nasdaq debut; US Solar grants potential bidder a third extension; Living REIT reassigns leases from insolvent Auckland

cup of coffee and someone taking notes on a pad

Literacy Capital (BOOK), the £176m UK private equity investment trust recovering from the write-down and sale of its holding in Cubo Work last month, has disposed of its residual interest in recruitment company Kernel Global for £6.5m. The secondary sale of mostly loan notes comes more than three years after BOOK sold most of its position to Three Hills Capital Partners for £19.7m. It originally invested £2.9m in Kernel between June 2018 and September 2019 which means total proceeds of £26.4m represent an overall return of nine times its original capital and an annual internal rate of return (IRR) of 54.2%. The latest sale was in line with the carrying value at 30 September and so has no impact on net asset value (NAV). “Logan Naidu, CEO of Kernel, has done a fantastic job in building the business and its brands globally since our original investment a little over eight years ago,” said fund manager Richard Pindar. BOOK shares rose 2%, or 6p, to 300p, below the 319p level they stood at before the Cubo announcement.

RTW Biotech Opportunities (RTW) says Windward Bio Group AG (WWB), a Swiss developer of treatments for respiratory and dermatologic diseases accounting for 0.8% of its portfolio at 31 October, saw its shares leap 68% on their flotation on Nasdaq on Friday. Windward sold 10m shares in the initial public offer (IPO) at $17 to raise $175m (£132m) with French pharmaceutical giant Sanofi providing a further $50m at the IPO price. Windward’s lead programme, WIN378, is currently in phase 2/3 trials for asthma and a phase 2 trial for chronic obstructive pulmonary disease. RTW first invested $5.3m in Windward’s series-A funding round in January 2025 and a further $1.7m in a $165m series-B round in May led by Orbimed, manager of Biotech Growth (BIOG).

Separately, the company said net asset value (NAV) fell 1.1% in October versus a 2.9% rise in the Nasdaq Biotech index and 3.8% decline for the Russell 2000 Biotech smaller company index. RTW said it had delivered a 13.9% annualised investment return since launch in October 2019 and remained positive on the medium-term outlook. “We expect biotech M&A to remain elevated, given patent expiries and the cash flows generated by obesity drugs. IPO volumes are normalising and aftermarket performance is healthy. Drug pricing policy uncertainty has largely resolved, and we continue to see limited to no impact from MFN [most favoured nation] pricing on the US businesses of our portfolio companies. AI and the growing contribution of Chinese science are improving productivity in drug discovery, and a growing number of emerging biotechs now have rapidly growing revenues. We expect the current [interest] rate tightening cycle to be shorter and less significant than in previous cycles.”

US Solar Fund (USF) has granted a third extension to the potential buyer assessing its assets. “The provision of additional time to review the operational performance of the remediated assets is believed to be the best option available to the company,” said USF’s board, which now expects the transaction to complete in the first quarter of next year. The £115m investment trust, whose wind-down is being managed by Amber Infrastructure, first disclosed the interested party prepared to pay a “significant premium” for its solar portfolio in May. The shares stand on a 38% discount to net asset value. They have risen 35% in the past six months but have lost nearly half their value over five years.

Living REIT (LIVE), the £328m social housing and retirement home real estate investment trust, has reassigned 29 of its 30 leases with Auckland Home Solutions after the struggling Durham-based housing association fell into insolvency. The leases have been transferred to Inclusion, a stronger housing association in York. LIVE shares added 0.5p to 71.8p. The 8%-yielder ended last week on a 23% discount to net asset value.

Gavin Lumsden
Written By Gavin Lumsden

Head of News

Leave a Reply

Your email address will not be published. Required fields are marked *